tbuckley/cabot-search huggingface dataset:
Sex-Specific Associations between Particulate Matter Exposure and Gene Expression in Independent Discovery and Validation Cohorts of Middle-Aged Men and Women
Authors: Karen Vrijens, Ellen Winckelmans, Maria Tsamou, Willy Baeyens, Patrick De Boever, Danyel Jennen, Theo M. de Kok, Elly Den Hond, Wouter Lefebvre, Michelle Plusquin, Hans Reynders, Greet Schoeters, Nicolas Van Larebeke, Charlotte Vanpoucke, Jos Kleinjans, Tim S. Nawrot
Journal: Environmental Health Perspectives (2016)

Background:Particulate matter (PM) exposure leads to premature death, mainly due to respiratory and cardiovascular diseases.Objectives:Identification of transcriptomic biomarkers of air pollution exposure and effect in a healthy adult population.Methods:Microarray analyses were performed in 98 healthy volunteers (48 men, 50 women). The expression of eight sex-specific candidate biomarker genes (significantly associated with PM10 in the discovery cohort and with a reported link to air pollution-related disease) was measured with qPCR in an independent validation cohort (75 men, 94 women). Pathway analysis was performed using Gene Set Enrichment Analysis. Average daily PM2.5 and PM10 exposures over 2-years were estimated for each participant’s residential address using spatiotemporal interpolation in combination with a dispersion model.Results:Average long-term PM10 was 25.9 (± 5.4) and 23.7 (± 2.3) μg/m3 in the discovery and validation cohorts, respectively. In discovery analysis, associations between PM10 and the expression of individual genes differed by sex. In the validation cohort, long-term PM10 was associated with the expression of DNAJB5 and EAPP in men and ARHGAP4 (p = 0.053) in women. AKAP6 and LIMK1 were significantly associated with PM10 in women, although associations differed in direction between the discovery and validation cohorts. Expression of the eight candidate genes in the discovery cohort differentiated between validation cohort participants with high versus low PM10 exposure (area under the receiver operating curve = 0.92; 95% CI: 0.85, 1.00; p = 0.0002 in men, 0.86; 95% CI: 0.76, 0.96; p = 0.004 in women).Conclusions:Expression of the sex-specific candidate genes identified in the discovery population predicted PM10 exposure in an independent cohort of adults from the same area. Confirmation in other populations may further support this as a new approach for exposure assessment, and may contribute to the discovery of molecular mechanisms for PM-induced health effects.Citation:Vrijens K, Winckelmans E, Tsamou M, Baeyens W, De Boever P, Jennen D, de Kok TM, Den Hond E, Lefebvre W, Plusquin M, Reynders H, Schoeters G, Van Larebeke N, Vanpoucke C, Kleinjans J, Nawrot TS. 2017. Sex-specific associations between particulate matter exposure and gene expression in independent discovery and validation cohorts of middle-aged men and women. Environ Health Perspect 125:660–669; http://dx.doi.org/10.1289/EHP370
Doctors beat computer programs in making diagnoses
Authors: Michael McCarthy
Journal: BMJ (2016)

102.1, 102.2, 102.3, 102.4, 102.5, 102.6, 102.7, 102.8, 102.9, 102.10, 210.2.1, 202.35.3

Doctors made the correct diagnosis more than twice as often as 23 commonly used online symptom checker websites, a new study has found. “In what we believe to be the first direct comparison of diagnostic accuracy, physicians vastly outperformed computer algorithms,” the researchers said.1

Each year millions of people go online to self diagnose. Many use symptom checker apps that let them enter their symptoms and receive a list of …
TCT-402 Feasibility of Robotic Percutaneous Coronary Intervention for Unprotected Left Main Stenosis in the Presence and Absence of Left Ventricular Hemodynamic Support with Impella
Authors: Ehtisham Mahmud, Arturo Dominguez, John Bahadorani, Mitul Patel, Ryan Reeves
Journal: Journal of the American College of Cardiology (2015)
Click chemistry improved wet adhesion strength of mussel-inspired citrate-based antimicrobial bioadhesives
Authors: Jinshan Guo, Gloria B. Kim, Dingying Shan, Jimin P. Kim, Jianqing Hu, Wei Wang, Fawzi G. Hamad, Guoying Qian, Elias B. Rizk, Jian Yang
Journal: Biomaterials (2016)
Salvage chemotherapy with high dose carboplatin + etoposide (HDCE) and peripheral blood stem cell transplant (PBSCT) in patients with germ cell tumors (GCT)
Authors: L. H. Einhorn, S. Williams, R. Abonour
Journal: Journal of Clinical Oncology (2006)

4549 Background: We began studies with HDCE for patients (pts.) with recurrent GCTs 20 years ago. During the past decade, better supportive care and use of PBSCT allowed outpatient therapy and more rapid hematopoietic recovery between the 2 courses of HDCE. Methods: Retrospective review of 184 consecutive pts. treated with HDCE at Indiana University from 2–96 to 12–04. Late relapse (&gt; 2 years from prior therapy) and primary mediastinal non-seminomatous germ cell tumor pts. were not offered HDCE. Cytoreduction with 0–2 courses of vinblastine + ifosfamide + cisplatin preceded HDCE. C dosage was 700 mg/M 2 × 3 and E 750 mg/M 2 × 3. A second course was given after hematologic recovery. Results: Toxicity was as previously described (JCO 18:3346, 2000). There were 3 drug- related mortalities. An additional 3 patients developed AML (2 fatal), and 1 glioma following CNS XRT for metastases. 11 pts. did not receive second course (8 due to progression or HDCE mortality). Median time to second course HDCE was 28 days (range 20 to 42). 116 of 184 pts. are alive and continuously (cont) NED (63%) with median followup 42 months (range 11 to 118). 113 (97%) of these are 12 + months NED. 5 additional pts. are currently NED with further therapy. Results are tabulated below. Conclusions: HDCE has a high cure rate with acceptable toxicity as salvage therapy for GCT pts. [Table: see text] [Table: see text]
GW27-e1046 Smoking Status-dependent Association between Monocyte Chemoattractant Protein-1 and Blood Pressure
Authors: Maki Komiyama, Rieko Takanabe, Koh Ono, Sayaka Shimada, Hiromichi Wada, Hajime Yamakage, Noriko Satoh-Asahara, Masaharu Akao, Tatsuya Morimoto, Akira Shimatsu, Yuko Takahashi, Koji Hasegawa
Journal: Journal of the American College of Cardiology (2016)
GW27-e1237 Curcumin analogue, Y-030, effectively suppressed hypertrophic responses in cardiomyocytes
Authors: Kana Shimizu, Yoichi Sunagawa, Masafumi Funamoto, Yasufumi Katanasaka, Hiroyuki Shibata, Hiromichi Wada, Koji Hasegawa, Tatsuya Morimoto
Journal: Journal of the American College of Cardiology (2016)
Les maladies de Creutzfeldt-Jakob et les maladies apparentées en France, de 1998 à 2000
Authors: L Capek, V Vaillant
Journal: Eurosurveillance (2003)

En France, le nombre de rapports de suspicion de MCJ a augmente de 1998 a 2000, probablement en raison d’une hausse des demandes de tests biologiques : respectivement 459 en 1998, 590 en 1999 et 823 en 2000. Pour les trois annees, la repartition par sexe etait similaire, avec un sex ratio (H/F) de 1,05. La proportion de suspicion de cas de moins de 50 ans est reste stable (16 % pour l’ensemble des rapports de 1998 a 2000). Le nombre de cas sporadiques de MCJ, confirmes ou probables, etait stable, avec un taux de mortalite de 1,38 pour un million en 1998, 1,56 en 1999, et 1,41 en 2000.
TCT-49 Underlying stenosis severity is independent of culprit plaque morphology in STEMI – an optical coherence tomography study
Authors: Olli A. Kajander, Natalia Pinilla-Echeverri, Ram Vijayaraghavan, Ravinay Bhindi, Dimitrios Alexopoulos, Anthony Fung, Heini Huhtala, Sanjit Jolly, Tej Sheth
Journal: Journal of the American College of Cardiology (2015)
NICE recommends new triple therapy option for type 2 diabetes
Authors: Jacqui Wise
Journal: BMJ (2016)

Dapagliflozin (marketed as Forxiga) has been recommended as part of triple therapy for patients with type 2 diabetes, giving doctors another prescribing option for patients with uncontrolled blood sugar.

Draft guidance from the National Institute for Health and Care Excellence (NICE) has recommended dapagliflozin in combination with metformin and a sulfonylurea as an option for treating type 2 …
Informatics and Data Analytics to Support Exposome-Based Discovery for Public Health
Authors: Arjun K. Manrai, Yuxia Cui, Pierre R. Bushel, Molly Hall, Spyros Karakitsios, Carolyn J. Mattingly, Marylyn Ritchie, Charles Schmitt, Denis A. Sarigiannis, Duncan C. Thomas, David Wishart, David M. Balshaw, Chirag J. Patel
Journal: Annual Review of Public Health (2017)

The complexity of the human exposome—the totality of environmental exposures encountered from birth to death—motivates systematic, high-throughput approaches to discover new environmental determinants of disease. In this review, we describe the state of science in analyzing the human exposome and provide recommendations for the public health community to consider in dealing with analytic challenges of exposome-based biomedical research. We describe extant and novel analytic methods needed to associate the exposome with critical health outcomes and contextualize the data-centered challenges by drawing parallels to other research endeavors such as human genomics research. We discuss efforts for training scientists who can bridge public health, genomics, and biomedicine in informatics and statistics. If an exposome data ecosystem is brought to fruition, it will likely play a role as central as genomic science has had in molding the current and new generations of biomedical researchers, computational scientists, and public health research programs.
TCT-365 The relationship between intravascular ultrasound (IVUS) plaque burden and lesion characteristics by Optical Coherence Tomography (OCT): a multimodality imaging study
Authors: Jacobo Pena, Yuliya Vengrenyuk, Usman Baber, Jason Kovacic, Samin K. Sharma, Annapoorna Kini, Jagat Narula, Pedro R. Moreno
Journal: Journal of the American College of Cardiology (2015)
Effects on androgen receptor nuclear import by docetaxel, cabazitaxel, abiraterone, and enzalutamide: Potential mechanism for cross-resistance in castration-resistant prostate cancer (CRPC).
Authors: Robert J. van Soest, Martin E. van Royen, Ellen S. de Morrée, Erik A.C. Wiemer, Ron H.J. Mathijssen, Ronald De Wit, Wytske M. van Weerden
Journal: Journal of Clinical Oncology (2013)

5064 Background: Recent reports have suggested that paclitaxel and docetaxel, which exert their therapeutic activity primarily through inhibition of microtubule function and mitosis, also impair androgen receptor (AR) signaling. AR signaling is the key therapeutic target for the newly available agents abiraterone and enzalutamide. A recent study suggested impaired efficacy of docetaxel when given after progression on abiraterone in patients with CRPC. To identify potential mechanisms of cross-resistance, we investigated whether and to what extent AR nuclear translocation is affected by docetaxel, cabazitaxel, abiraterone and enzalutamide. Methods: Hep3B cells stably expressing GFP labeled AR were used for AR translocation studies. Cells were seeded on a cover slip in steroid-stripped medium (DCC) and treated with docetaxel (1 µM), cabazitaxel (1 µM), abiraterone (6 µM) and enzalutamide (1 µM). The anthracenedione mitoxantrone (100 nM) that does not target the microtubule cytoskeleton was used as a control cytotoxic agent. Following incubation for 48 hours, the synthetic androgen R1881 was added to study dynamics of AR nuclear import by time-lapse confocal microscopy. Results: Docetaxel and cabazitaxel inhibited R1881 induced AR nuclear translocation with 21% and 34% respectively compared to control, while mitoxantrone did not affect AR transport. Abiraterone inhibited AR translocation with 58% and enzalutamide completely blocked AR translocation. Conclusions: These data point towards a role for microtubules in AR nuclear transport and an additional mechanism of taxane activity in CRPC. Docetaxel, cabazitaxel, abiraterone and enzalutamide all interfere with AR nuclear transport, which is a crucial step in AR signaling. Our findings identify and provide insight in a potential mechanism of clinical cross-resistance between the two taxanes currently registered for treatment in CRPC and the novel agents abiraterone and enzalutamide. Further investigations are warranted in order to define if this potential cross-resistance impacts the most suitable treatment sequence for these drugs in CRPC.
C9ORF72 interaction with cofilin modulates actin dynamics in motor neurons
Authors: Rajeeve Sivadasan, Daniel Hornburg, Carsten Drepper, Nicolas Frank, Sibylle Jablonka, Anna Hansel, Xenia Lojewski, Jared Sterneckert, Andreas Hermann, Pamela J Shaw, Paul G Ince, Matthias Mann, Felix Meissner, Michael Sendtner
Journal: Nature Neuroscience (2016)
A phase 1b study of combined angiogenesis blockade with nesvacumab, a selective monoclonal antibody (MAb) to angiopoietin-2 (Ang2) and ziv-aflibercept in patients with advanced solid malignancies.
Authors: Kyriakos P. Papadopoulos, Donna M. Graham, Anthony W. Tolcher, Albiruni R. A. Razak, Amita Patnaik, Philippe L. Bedard, Drew Warren Rasco, Alex Amaya, Kathleen N. Moore, Jason A. Konner, Daniela Matei, Lainie P. Martin, Lieve Adriaens, Carrie M. Brownstein, Israel Lowy, Bo Gao, Ana Kostic, A Thomas DiCioccio, Pamela Trail, Lillian L. Siu
Journal: Journal of Clinical Oncology (2014)

2522 Background: Nesvacumab (N) is a selective, human Ang-2 MAb, that potently blocks Ang2 signaling through the Tie2 receptor. Ziv-aflibercept (Z) is a recombinant human fusion protein and a decoy receptor for VEGF-A, VEGF-B, and placental growth factor. In mouse xenograft models, N+Z significantly inhibited tumor growth and angiogenesis compared to either agent alone. Methods: This phase 1b dose escalation study seeks to evaluate safety, pharmacokinetic (PK), and pharmacodynamics (PD), to find a recommended phase 2 dose (RD), and to explore antitumor activity of N+Z administered IV Q2W in patients (pts) with advanced solid tumors. Pts were treated at 1 of 5 dose levels of combination treatment [6mg/kg N + 2mg/kg Z (6N/2Z), 12N/2Z, 20N/2Z, 12N/4Z, 20N/4Z]. Results: 30 pts [11M/19F; median age 60.5 (range 25-89); ECOG PS 0(5)/1(25)] were enrolled. Two pts experienced DLT: esophageal variceal bleeding (12N/4Z) and prolonged proteinuria (20N/4Z). MTD was not defined. Most common treatment-related AEs (TRAEs) were HTN (19), fatigue (13), proteinuria (8), diarrhea (6), stomatitis (6), and decreased appetite (5). Grade ≥ 3 TRAEs were hypertension (11), proteinuria (2) and fatigue (1). Proteinuria was dose related, but resolved with dose modification. Four pts discontinued treatment due to AE: rectal obstruction, skin ulcers, esophageal variceal bleeding, and fatigue. Two pts achieved PR: 1 pt with CRC previously treated with bevacizumab (32+ wk) and 1 pt with OvCa (19 wks);15 patients achieved disease control with median duration of 29 wks; 7 pts experienced SD ≥16 wks. Across all dose levels, the PK and resulting systemic exposures of both N and Z were not affected by co-administration of the 2 agents. Each agent appeared linear and dose-proportional over the Q2W dosing interval. Total circulating serum Ang2 and VEGF appeared saturated following treatment at all dose levels. Conclusions: Co-administration of N+Z in patients with advanced cancer is generally well tolerated. TRAEs were as expected for anti-VEGF therapy. Enrollment into expansion cohorts with a planned dose of 20N/4Z with and without chemotherapy is ongoing. Clinical trial information: NCT01688960.
TCT-50 Peri-strut Low Intensity Area Assessed By Mid-term Follow-up Optical Coherence Tomography May Predict Target Lesion Revascularization After Stent Implantation
Authors: Koji Kuroda, Hiromasa Otake, Toshiro Shinke, Tomofumi Takaya, Hiroto Kinutani, Masaru Kuroda, Hachidai Takahashi, Daisuke Terashita, Daiji Kashiwagi, Kenzo Uzu, Natsuko Tahara, Yuto Shinkura, Yoshinori Nagasawa, Ken-ichi Hirata
Journal: Journal of the American College of Cardiology (2015)
Blood Lead Levels in Children Aged &lt;5 Years — United States, 2007–2013
Authors: Jaime Raymond, Mary Jean Brown
Journal: MMWR Morbidity and Mortality Weekly Report (2016)

This report provides data concerning childhood blood lead levels (BLLs) in the United States during 2007-2013. These data were collected and compiled from raw data extracts sent by state and local health departments to CDC's Childhood Blood Lead Surveillance (CBLS) system. These raw data extracts have been de-identified and coded into a format specifically for childhood lead reporting. The numbers of children aged <5 years reported to CDC for 2013 with newly confirmed BLLs ≥10 µg/dL are provided in tabular form by month (Table 1) and geographic location (Table 2). The incidence of BLLs ≥10 µg/dL is reported by age group for 2007-2013 (Table 3). The numbers of children aged <5 years with BLLs 5-9µg/dL for 2013 are reported (Table 4). For the period 2007-2013, the numbers of children newly confirmed with BLLs ≥70 µg/dL are summarized (Figure 1) as well as the percentage of children with BLLs ≥5 µg/dL (Figure 2). This report is a part of the Summary of Notifiable Noninfectious Conditions and Disease Outbreaks - United States, which encompasses various surveillance years but is being published in 2016 (1). The Summary of Notifiable Noninfectious Conditions and Disease Outbreaks appears in the same volume of MMWR as the annual Summary of Notifiable Infectious Diseases (2).
Hypothalamic-Pituitary Axis Dysfunction in Survivors of Childhood CNS Tumors: Importance of Systematic Follow-Up and Early Endocrine Consultation
Authors: Wassim Chemaitilly, Gregory T. Armstrong, Amar Gajjar, Melissa M. Hudson
Journal: Journal of Clinical Oncology (2016)

The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice. An 11-year-old male with a history of metastatic tectal plate low-grade glioma who was diagnosed at age 2.8 years transferred his care to the long-term follow-up clinic. He completed treatment with multiagent chemotherapy-carboplatin, vincristine, temozolomide, procarbazine, lomustine, and thioguanine-at age 4.5 years and did not require radiotherapy. At primary diagnosis, he presented with hydrocephalus that required ventriculoperitoneal shunt placement, with a subsequent shunt revision at age 6 years. Residual metastatic tumors in the third and fourth ventricles and in the suprasellar region remained stable for more than 5 years. The patient achieved normal developmental milestones and was not taking medications. He was offered screening for hypothalamic-pituitary axis (HPA) dysfunction because of his suprasellar lesion. His height was at the 25th percentile for chronological age, with decline from the 50th percentile noted during the preceding 18 months ( Fig 1 , point c). Pubertal stage was Tanner 4 for pubic hair and penile size, which contrasted with small testes (4.5 mL). Pubic hair and voice changes were noticed 2 to 3 years before this visit. Plasma testosterone level was consistent with Tanner 4 (255 ng/dL = 8.9 nmol/L). An x-ray of the left hand revealed a notably advanced bone age of 15.5 years. Plasma free T4, thyroid-stimulating hormone (TSH), and 8 am cortisol levels were normal. The patient was referred to the endocrinology clinic where he was diagnosed with growth hormone deficiency and was started on replacement therapy. He reached his final adult height of 144.1 cm at age 13.3 years ( Fig 1 , point d).
TCT-572 Final 5-Year Outcome After Implantation of Zotarolimus-Eluting Resolute Stents Versus Everolimus-Eluting Xience V Stents in the Broad Patient Population of the Randomized TWENTE Trial
Authors: Clemens von Birgelen, Liefke C. van der Heijden, Marlies M. Kok, Gert van Houwelingen, Martin G. Stoel, Frits H. de Man, Hans W. Louwerenburg, Gerard C. Linssen, Kenneth Tandjung, Mounir W. Basalus, Job van der Palen, Marije M. Löwik
Journal: Journal of the American College of Cardiology (2015)
TCT-79 Efficacy of Cangrelor in Lesions with High-Risk and Low-Risk Angiographic Characteristics: The CHAMPION PHOENIX trial
Authors: Gregg W. Stone, Philippe Genereux, Harvey D. White, C. Michael Gibson, Christian Hamm, Kenneth Mahaffey, Matthew J. Price, Jayne Prats, Robert Harrington, Deepak L. Bhatt
Journal: Journal of the American College of Cardiology (2015)
Acute Myeloid Leukemia (AML) with t(6;9)(p23;q34) Defines a Very Poor Risk Leukemia Subgroup with Distinguishing Clinicopathological Features: A United States (US) Cytogenetics Intergroup Study of 62 AML and MDS Cases.
Authors: Marilyn L. Slovak, Clara D. Bloomfield, Holly Gundacker, Gordon Dewald, Frederick R. Appelbaum, Richard A. Larson, Martin S. Tallman, Cheryl Willman, Yaddanapudi Ravindranath, Todd A. Alonzo, Andrew Carroll, Betsy Hirsch, Susana Raimondi, Nyla A. Heerema
Journal: Blood (2004)
TCT-487 Temporal Associations Between Myocardial Infarction, Major Bleeding and Mortality Risk in ACS Patients Undergoing PCI: Insights from the PROMETHEUS Cohort
Authors: Usman Baber, Jennifer Chao, Jaya Chandrasekhar, Samantha Sartori, Melissa Aquino, Annapoorna Kini, Sunil Rao, William Weintraub, Sandra Weiss, Craig E. Strauss, Samir Kapadia, Timothy D. Henry, Anthony DeFranco, Joseph B. Muhlestein, Catalin Toma, Stuart J. Pocock, Stuart Y. Keller, Mark B. Effron, Brian A. Baker, Roxana Mehran
Journal: Journal of the American College of Cardiology (2015)
Comparison of Outcomes of Unrelated Bone Marrow and Umbilical Cord Blood Transplants in Children with Hematologic Malignancies: Single Center Study in Korea.
Authors: Nak-Gyun Chung, Bin Cho, Young-Shil Park, Dae-Chul Jeong, Pil-Sang Jang, Hack-Ki Kim
Journal: Blood (2004)
TCT-448 Differential Prognostic Impact between 1st and 2nd Generation Drug-Eluting Stents in Coronary Bifurcation Lesions: Patients-Level Analysis of the Korean Bifurcation Pooled Cohorts
Authors: Joo Myung Lee, Joo-Yong Hahn, Jeehoon Kang, Kyung Woo Park, Woo Jung Chun, Seung-Woon Rha, Cheol Woong Yu, Jin-Ok Jeong, Junghan Yoon, Yangsoo Jang, Seung-Jea Tahk, Hyeon-Cheol Gwon, Bon-Kwon Koo, Hyo-Soo Kim
Journal: Journal of the American College of Cardiology (2015)
Drug-Drug Interactions With Oral Antineoplastic Agents
Authors: Sandeep Parsad, Mark J. Ratain
Journal: JAMA Oncology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
GW27-e1240 The relation between apoA and the severity of coronary artery lesions in Chinese Type 2 diabetics with coronary heart disease: An assessment based on Gensini scores
Authors: Liu Dinghui, Jianrui Zheng, Shujie Yu, Bin Zhou, Lin Wu, Min Wang, Xiaoxian Qian
Journal: Journal of the American College of Cardiology (2016)